🫀 Cardiovascular Update: Lilly Acquires Verve, AI Scans Cut NHS Costs, GPs Get New HF Guidance and More
In this episode, we’re diving into the latest innovations transforming cardiovascular care from AI-powered diagnostics to gene-editing therapies and game-changing clinical guidelines.
📌 In This Episode:
✔️ Broad Institute & Bayer renew a precision cardiology alliance to unlock new genetic insights
✔️ NICE empowers GPs to prescribe life-saving heart failure drugs earlier
✔️ Basket trials offer smarter, more targeted research methods
✔️ New data links atrial fibrillation + HFpEF to increased mortality
✔️ AI-driven 3D scans help the NHS reduce unnecessary procedures and save £9.5M
✔️ Eli Lilly’s $1.3B acquisition of Verve Therapeutics accelerates single-dose gene therapies
✔️ Smart foot scanners detect heart failure risks up to 13 days in advance
✔️ €27M EuroHeartPath AI project rolls out across 15 countries
✔️ Adona completes a successful first-in-human shunt trial for personalized HF therapy
✔️ Japan’s MedHub-AI and Terumo deploy wire-free, AI-driven FFR tech
📈 Whether you’re a healthcare leader, clinician, researcher, or investor, this update is packed with actionable insights into the evolving cardiovascular landscape.
📢 Stay Ahead in Cardiovascular Research!
✅ Like, share, and subscribe for weekly updates on Cardiovascular breakthroughs
#Cardiology #HeartHealth #GeneTherapy #AIinHealthcare #HFpEF #AFib #PrecisionMedicine #CardiovascularInnovation #HealthcareAI #LucidQuest #HeartFailure #BasketTrials #MedicalResearch #LQVentures